MaxCyte's net income is $-39M, below the Materials sector average of $10B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Loading...
Loading...
As of the most recent data (March 2026), MXCT shows a net income of $-39M. That compares with $-42M in the prior-year period — up 6.4% year over year. That is below the Materials sector average of $10B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MXCT's net income is now $-39M (was $-42M) — a 6.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether MaxCyte is outperforming or lagging.
The Materials sector average net income is about $10B. MaxCyte is at $-39M, which is lower that average. That is roughly 100.4% below the sector mean. Use the comparison chart on this page to see how MXCT stacks up against individual peers as well.
Tracking MXCT's net income over time shows whether MaxCyte is scaling, shrinking, or reshaping that part of the business. The current reading is $-39M That compares with $-42M in the prior-year period — up 6.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has MaxCyte's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-39M) with ownership activity and broader fundamentals.